Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019
- Phase 2 clinical data demonstrated that subcutaneous administration of selatogrel resulted in a potent, rapid and sustained platelet inhibition effect, and was safe and well tolerated
- The company is preparing for a Phase 3 study for the treatment of a suspected acute myocardial infarction
Allschwil, Switzerland – September 3, 2019
Idorsia Ltd (SIX: IDIA) today announced that the positive results of two Phase 2 clinical studies with selatogrel, a highly-selective P2Y12 receptor antagonist, were presented at the European Society of Cardiology 2019 Congress in Paris, France. The company is now in the process of preparing for a Phase 3 study to investigate the efficacy and safety of selatogrel following subcutaneous self-administration for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI.
An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle is suddenly decreased or completely cut off. It is usually caused by a blood clot or blockage in one or more of the coronary vessels supplying blood to the heart muscle. An AMI requires immediate treatment and medical attention, as any delay in intervention can result in irreversible damage to the heart muscle. The American Heart Association estimates that each year more than 600,000 persons living in the US will suffer their first heart attack and around 200,000 will suffer a recurring heart attack.
AMI is associated with a 30% mortality rate and about half of these deaths occur prior to arrival at the hospital. As a result, early action is crucial for survival, however there are no treatment options available for the critical time from onset of AMI symptoms to first medical contact. The need for an early intervention has been highlighted by the guidelines of the European Society of Cardiology and the American College of Cardiology / American Heart Association, which identified the prehospital phase as the most critical and reiterated that efforts must be made to reduce the delay for treatment initiation to reduce death.
Idorsia is developing selatogrel, a potent, fast-acting, reversible, and highly-selective P2Y12 receptor antagonist, for single subcutaneous self-administration for the treatment of a suspected AMI in patients with a history of AMI.
Martine Clozel, MD and Chief Scientific Officer, commented:
“It is well documented that AMI is caused by blood vessel occlusion, driven by the formation of a platelet-rich thrombus which can be prevented by P2Y12 receptor antagonists. This therapeutic class has been used in the treatment of millions of patients globally and as such, the safety and efficacy profiles are well-established. However, until now the method of administration or the delayed onset of effect means that currently available treatments do not have the desired profile to cover the critical time from onset of AMI symptoms to first medical contact. Scientists at Idorsia have discovered selatogrel, which has great potential to fill this gap for early treatment of AMI.”
About the clinical development of selatogrel
Subcutaneous administration of selatogrel by a healthcare professional has been studied in two Phase 2 clinical studies in patients with stable coronary artery disease (CAD) and in patients with AMI, which were both presented at ESC 2019.
Phase 2 study in adults with stable CAD presented at ESC
Professor Robert Storey, BM, Professor of Cardiology, University of Sheffield, UK, gave an oral presentation entitled "Selatogrel, a novel P2Y12 receptor antagonist, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients".
The study was a multicenter, double blind, randomized, placebo-controlled study assessing the pharmacodynamics, pharmacokinetics, tolerability and safety of a single subcutaneous injection of selatogrel either in the thigh or in the abdomen at 2 different doses in adults with stable coronary artery disease. In the study, 345 patients (mean age 65 y; 20% female; 31% diabetes) received selatogrel 8 mg (n=114), selatogrel 16 mg (n=115) or placebo (n=116). 97% were on background therapy with aspirin (or its derivative carbasalate) and 35% on oral P2Y12 receptor antagonist (clopidogrel 23%, prasugrel 4%, ticagrelor 8%). The primary objective of the study was to characterize inhibition of platelet aggregation relative to placebo. Platelet reactivity was assessed by VerifyNow PRU (P2Y12 reaction units) test before and 15 min, 30 min and 1, 2, 4, 8 and 24 h after injection. Light-transmittance aggregometry (LTA; ADP 20 uM) was also performed.
The primary endpoint, patients (responders) having PRU < 100 starting at 30 min and lasting ≥3 h after a single study treatment injection, was achieved in 89% of patients receiving selatogrel 8 mg, and 90% of patients receiving selatogrel 16 mg compared with 16% in the placebo group (P<0.0001). Inhibition of platelet aggregation was observed as early as 15 min post-dose, PRU values (mean±SD) were 10±25 with selatogrel 8 mg, 5±10 with selatogrel 16 mg and 163±73 with placebo. PRU levels were maintained at 2 and 4 h for both doses and gradually returned to pre-dose levels by 24 h post-dose. Light-transmittance aggregometry (LTA) results were consistent with the VerifyNow results. Pharmacodynamic responses were similar for thigh and abdomen injection sites and were consistent across the different subgroups (age, sex, BMI, presence of chronic kidney disease or diabetes). Selatogrel was well tolerated: mild dyspnea (or moderate dyspnea, n=1, with 16 mg) occurred in 5% and 9% of patients with selatogrel 8 mg and 16 mg, respectively, vs 0% with placebo; dizziness occurred in 4% and 4% vs 1%, respectively, without significant hemodynamic or ECG changes. Bleeding events occurred in 9.6% and 4.3% of patients with selatogrel 8 mg and 16 mg, respectively, vs 6.9% with placebo. All bleeding events were of mild intensity except one of moderate intensity, which was reported in the placebo group. No major bleeding event was reported during the study.
Prof. Robert Storey commented:
“Pivotal trials of anti-platelet drugs in patients with AMI have demonstrated the importance of rapid onset of action yet, more recently, we have learnt that the onset of action of oral anti-platelet drugs may be delayed by hours in this setting. In this context, the properties of selatogrel that we have demonstrated in patients with CAD are particularly exciting and demonstrate the potential for further advancing the early management of AMI by delivering rapid and consistent platelet inhibition with a simple single subcutaneous administration.”
Phase 2 study in adults with AMI presented at ESC
Professor Peter Sinnaeve, MD, Department of Cardiology, University Hospitals Leuven, Faculty of Medicine, University of Leuven, Belgium, gave an oral presentation entitled "Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 receptor antagonist, in patients with acute myocardial infarction”.
The study was a multi-center, open-label, randomized, exploratory study to assess the onset of platelet aggregation inhibition after a single subcutaneous injection of selatogrel in adults with acute myocardial infarction. In this study, 47 patients (median age 69 y; 72% male; 62% STEMI; 94% Killip class 1) received 8 mg (n=24) or 16 mg (n=23) selatogrel. Study-treatment concomitant medications included acetylsalicylic acid (98%), P2Y12 receptor antagonists (96%), heparins (94%), statins (94%), nitrates (68%) and morphine (38%). Blood samples were collected at baseline and at 15, 30, and 60 min post-dose and platelet reactivity (expressed as PRU) was evaluated using VerifyNow. The primary objective of the study was to assess the inhibition of platelet aggregation 30 minutes after a single subcutaneous injection of selatogrel.
The response to treatment as defined by PRU < 100 at 30 min post-dose, was achieved in 91% and 95% of patients with selatogrel 8 and 16 mg, respectively. Response rates were independent from STEMI/NSTEMI diagnosis, age and sex. PRU below 100 was observed as early as 15 min (8 mg: 75% of patients; 16 mg: 91% of patients) and sustained for up to 60 min post-dose (8 mg: 75% of patients; 16 mg: 96% of patients). Overall, 43% of patients had ≥1 treatment-emergent adverse event (TEAE), which were mainly of mild/moderate intensity. Ventricular tachycardia ([VT] 8 mg: 4/24; 16 mg: 3/23) was the most frequent TEAE and was reported as serious AE in two patients: one patient receiving 8 mg and one patient receiving 16 mg selatogrel. Post-procedural hemorrhage (of mild intensity) occurred in one patient after percutaneous coronary intervention with radial access.
Prof. Peter Sinnaeve commented:
“The concept that “time is muscle” in relation to AMI has been around for nearly 30 years, yet we still don’t have anything to offer our patients in the time between onset of AMI symptoms and first medical contact, which can often be several hours. The anti-platelet effect and safety profile observed in this Phase 2 program of selatogrel suggests that it has the potential to overcome limitations of available oral P2Y12 receptor antagonist therapies in the early management of AMI. Any reduction in the delay for treatment initiation could mean the difference between life and death, so we must evaluate this opportunity.”
Guy Braunstein, MD and Head of Idorsia Global Clinical Development, added:
“The Phase 2 data demonstrate that subcutaneous administration of selatogrel 16mg in patients with stable CAD and patients with AMI has a rapid onset of action, within 15 minutes, with the effect extending over 4-8 hours. Based on the speed at which selatogrel takes effect, the duration of that effect, and the safety and tolerability profile, self-administration of selatogrel at the very onset of symptoms of a suspected AMI has potential as a highly innovative approach to AMI management.”
In consultation with health authorities, Idorsia is preparing a large, international, multi-center, Phase 3 study to investigate the efficacy and safety of subcutaneous self-administration of selatogrel for the treatment of a suspected AMI in patients with an history of AMI. Participating patients will be trained on when to inject and instructed on how to self-administer treatment. An integrated drug delivery device is being developed through usability and reliability studies to ensure functional efficacy can be demonstrated ahead of the Phase 3 study.
Jean-Paul Clozel, MD, and Chief Executive Officer, concluded:
“As a cardiologist, I find this project incredibly exciting. I think everyone understands that this novel concept of self-administration at onset of symptoms could be a game-changer in the management of AMI. As a CEO, I am also excited for the impact this product could have on the future of our company. As some of our Phase 3 programs are approaching completion, the timing is perfect to bring new innovative projects forward and deliver on our vision to help more patients.”
Notes to the editor
Professor Robert Storey
Professor Robert Storey is Professor of Cardiology at the University of Sheffield, Sheffield, UK, where he has headed a thrombosis research group since 2002 and is director of the Cardiovascular Research Unit. In addition, Prof. Storey is Academic Director and honorary Consultant Cardiologist for the Cardiology and Cardiothoracic Surgery Directorate, Sheffield Teaching Hospitals NHS Foundation Trust. He has a special interest in the management of ischaemic heart disease, including acute coronary syndromes and coronary intervention.
He was Chair of the Working Group on Thrombosis of the European Society of Cardiology (ESC) from 2012-2014 and has been a Task Force member for ESC guidelines on chronic coronary syndromes (2019), non-ST-elevation acute coronary syndromes (2011 and 2015) and dyslipidaemias (2011). He served as a member of the executive committees for the DISPERSE2, PLATO and PEGASUS-TIMI 54 studies, leading the platelet function substudies for these trials, and of the steering committees for the TRA-CER, EPICOR, ATLANTIC and AUGUSTUS studies. He is currently chief investigator for a phase II study of selatogrel in stable coronary artery disease patients and a member of the steering committees for the COMPLETE, RAPID CTCA, SENIOR RITA and CLEAR SYNERGY studies.
About Professor Peter Sinnaeve
Dr Peter Sinnaeve graduated summa cum laude from the University of Leuven, Belgium, in 1994, and was trained as a cardiologist at the same institution. He subsequently obtained a PhD degree in Medical Sciences, after doctoral research in cardiovascular gene therapy. In 2002-2003, he was a post-doctoral fellow at the Duke Clinical Research Institute in the USA as recipient of a Fullbright scholarship. Dr Sinnaeve then joined the staff at the University Hospitals Leuven, Belgium. He is currently professor at the University of Leuven and is a Clinical Investigator for the Flemish Fund for Scientific Research. His clinical expertise lies in acute cardiac care, interventional cardiology, pericardiology, as well as cardiac rehabilitation, while his current research focuses on antithrombotic therapies and the genomics of acute coronary syndromes. He is active in a variety of national and international boards and is involved in several clinical trials in cardiovascular disease as a steering or executive committee member. To date, Dr Sinnaeve has (co)authored 162 peer-reviewed papers and 26 book chapters.
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.
Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet – the ideal constellation to bringing R&D efforts to business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 (0) 58 844 10 10
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Brunel stops activities in BIS - Earnings outlook substantially adjusted downwards22.10.2019 20:00:00 CEST | Press release
Amsterdam, 22 October 2019 BIS activities are loss-making and causing one-off costs Profitability further under pressure due to the performance in the Netherlands and expected tougher conditions in Germany After careful consideration, Brunel has decided to stop Brunel Industrial Services (BIS) in Texas, US. Since 2017, BIS has worked on various construction and maintenance projects, including large projects in shale oil & gas. As announced in Brunel´s Q2 results this August, we encountered issues with a project for a water treatment plant, which we won in 2018, leading to a one-off loss of EUR 5.5 million. We replaced the general manager and rebuild the organization, but at the same time we saw the market for shale oil & gas experiencing a slowdown with changing clients’ behavior in their contracting model from T&M to fixed pricing. As a consequence, our BIS-activities in Q3 were at a very low level, causing a disbalance with our organizational capacity and resulting in significant ope
Telenor Group and NENT Group to merge Canal Digital and Viasat Consumer22.10.2019 19:14:00 CEST | Press release
(Fornebu/Stockholm, 22 October 2019) Telenor Group and Nordic Entertainment Group (NENT Group) today announced the formation of a new company that combines Canal Digital and Viasat Consumer (satellite pay-TV & broadband-TV operations). This will create a vibrant Nordic TV distribution business and capture synergies in a maturing direct-to-home (DTH) segment. Telenor and NENT Group will each hold 50 percent of the new company. Highlights: The combination generates a Nordic player with combined net sales of approximately NOK 7 billion and around 1.25 million subscribers (Q2 2019). The combination is expected to yield peak annual cost synergies of approximately NOK 600 million, with full effect from 2022. Integration and other related costs are expected to total approximately NOK 830 million. The company will be headquartered in both Oslo and Stockholm, and will also have a substantial presence in Copenhagen. The joint venture will operate at arm’s length to its parents. The Nordic consum
Telenor og NENT slår sammen Canal Digital og Viasat Consumer22.10.2019 19:14:00 CEST | Pressemelding
(Fornebu / Stockholm, 22. oktober 2019) Telenor og Nordic Entertainment Group (NENT) kunngjør i dag opprettelsen av et nytt selskap som kombinerer Canal Digital og Viasat Consumer (satellitt- og bredbånds-TV). Dette vil skape en fremoverlent nordisk TV-distribusjonsvirksomhet og hente synergier i et modent direct-to-home segment (DTH). Telenor og NENT vil hver eie 50 prosent av det nye selskapet. Nøkkeltall Transaksjonen resulterer i et selskap med en total omsetning på ca 7 milliarder NOK og i overkant av 1,25 millioner kunder (Q2 2019). Transaksjonen er forventet å gi årlige synergier på inntil 600 millioner NOK med helårseffekt fra 2022. Det er forventet inntil 830 millioner NOK i integrasjonskostnader. Selskapet vil ha hovedkontorer i både Oslo og Stockholm, og vil også ha en betydelig tilstedeværelse i København. Selskapet vil operere på armlengdes avstand i forhold til eierne. Det nordiske kundetilbudet vil fokusere på satellittdistribuert betal-TV (DTH) og strømmetjenester, sam
Scanship Holding ASA : Presentation of 3Q 2019 Trading update, including contract awards on 22 October22.10.2019 16:59:00 CEST | Press release
Please find enclosed the presentation of the 3Q 2019 Trading update for Scanship Holding ASA, including the contract awards received the 22 October on the order backlog. For further queries, please contact: Henrik Badin - CEO Scanship Holding ASA Tel: +47 90 78 98 25 Email: firstname.lastname@example.org ABOUT SCANSHIP HOLDING ASA Scanship delivers world leading solutions for cleaner oceans in the Cruise and Aquaculture industries. Scanship provides advanced technologies for processing waste and purifying wastewater. Owners operating Scanship systems have the solution to convert all waste and wastewater into clean energy and purified water which meets the highest international discharge standards. Any residuals from the Scanship processes can be recovered for reuse. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment 22102019_Scanship Holding ASA - 3Q2019 Trading Update with contract awards after presentation
European Commission has published a decision on the compatible state aid22.10.2019 16:58:00 CEST | Press release
European Commission has published a decision on the compatible state aid confirming that the measures proposed by the Republic of Lithuania to reduce the costs of maintenance of LNG terminal are compatible with the internal market and fulfil the criteria for state aid. The measures approved in this decision will create legal preconditions to reduce the costs of maintenance of LNG terminal by the amount of up to EUR 135,5 mln. until 2024. Further decisions will be approved by the Board and the General Meeting of Shareholders of AB Klaipedos nafta. More information on the approval of the European Commission is provided on the following: https://ec.europa.eu/competition/elojade/isef/case_details.cfm?proc_code=3_SA_53074 Jonas Lenkšas, Chief Financial Officer, +370 694 80594
Scanship Holding ASA : Scanship awarded clean ship system contracts and increases backlog to new record high22.10.2019 15:45:00 CEST | Press release
Scanship Holding ASA, through its subsidiary Scanship AS, has been awarded contracts with an European shipbuilder for the supply of a total Scanship clean ship system for two luxury and expedition class type of cruise ships. The newbuilds will enter service in 2022 and 2023. The contracts also include options for further deliveries to 6 newbuilds planned to enter service from 2024 and onwards. The luxury vessels will be delivered to one of the major US based shipowners. More details will be announced in relation to these contracts at a later stage. The Scanship contracts includes delivery of systems for food waste processing, garbage handling and wastewater purification, to meet the industry's highest environmental regulations worldwide and particularly the new regulations now being enforced in the Baltic Sea. This latest order intake accumulates the total order backlog to a record high level of NOK 710 million firm and NOK 570 million of optional contracts. For further queries, please